[Form 4] Pacific Biosciences of California, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), reported a routine sale of shares to cover tax withholding upon RSU vesting. The Form 4 discloses that on 08/18/2025 he disposed of 26,836 shares at a weighted average sale price of $1.311 per share (sale prices ranged from $1.30 to $1.32). After the transaction he beneficially owns 1,920,035 shares. The filing explains the shares were automatically sold to satisfy tax withholding obligations related to restricted stock unit vesting. The Form 4 was signed by an attorney-in-fact on 08/20/2025.

Insights

Corporate Governance Expert

TL;DR: Routine RSU tax-withholding sale by an executive, leaving substantial retained ownership; not a governance-red flag.

The disclosure indicates an automatic sale of 26,836 shares to satisfy tax obligations arising from RSU vesting, a common administrative practice. Retaining 1,920,035 shares suggests continued alignment with shareholders. There are no indications of opportunistic trading or a larger divestiture. The filing is complete with a weighted average sale price and range provided as required.

Securities Analyst

TL;DR: Small, routine insider sale; minimal market impact given size relative to total reported holdings.

The transaction was coded as a sale to cover tax withholding, with 26,836 shares sold at a weighted average price of $1.311 (range $1.30–$1.32). The post-transaction beneficial ownership of 1,920,035 shares is explicitly stated. No derivative transactions or other dispositions are reported. This Form 4 provides the standard disclosures expected for RSU vesting-related sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Oene Mark

(Last) (First) (Middle)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.,

1305 O'BRIEN DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S		26,836(1)	D	$1.311(2)	1,920,035	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. This sale price represents the weighted average sale price of the shares sold ranging from $1.30 to $1.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Remarks:

Chief Operating Officer

	/s/ Michele Farmer, Attorney-in-fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PACB insider Mark Van Oene report on Form 4?

He reported an automatic sale of 26,836 shares on 08/18/2025 to cover tax withholding from RSU vesting and now beneficially owns 1,920,035 shares.

At what price were the PACB shares sold in the Form 4?

The weighted average sale price was reported as $1.311 per share, with individual sale prices ranging from $1.30 to $1.32.

Why were the PACB shares sold according to the Form 4?

The filing states the shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.

How does the Form 4 identify Mark Van Oene's role at PACB?

The filing lists him as an Officer with the remark Chief Operating Officer.

When was the Form 4 signed and by whom?

The Form 4 was signed on 08/20/2025 by Michele Farmer, Attorney-in-fact for the reporting person.